Dwight Morrow, Ph.D.

Vice President, Platform and Innovation

Dwight Morrow joined Rubius in 2019, and serves as Vice President of Platform and Innovation, leading innovation across the RED PLATFORM® with a focus on hematopoietic stem and progenitor cells, novel gene delivery and expression technologies, and translation of in vivo erythropoiesis to in vitro Red Cell Therapeutic™ (RCT) production.

Dwight brings 25 years of experience in early target and drug discovery and development, including CMC, IND-enabling studies, GLP tox, pre-IND and IND submission. Prior to his role at Rubius, he was the Vice President of Preclinical Development at Magenta Therapeutics, where he helped build the company from a startup to a clinical stage company and served as project head for its lead hematopoietic stem cell program from inception through IND filing and Phase 1 clinical programs. Before that, Dwight spent 17 years at GlaxoSmithKline in the High Throughput Screening department, and then as Director of Discovery in the Stem Cell and Regenerative Medicine Units before becoming Senior Director of Target Sciences, responsible for the target validation strategy for Metabolic and Cardiovascular therapy areas, including diabetes, kidney diseases, muscle and cardiovascular diseases.

Earlier in his career, Dwight worked in genetics, molecular and cellular biology with a focus on technology development, including novel molecular biological techniques, yeast genetics and chromosome manipulation.

Dwight has been active for more than 30 years in the scientific community by presenting at conferences and publishing scientific papers and book chapters. Additionally, Dwight is listed on seven patents and has received numerous grants and awards throughout his career.

Dwight holds a Ph.D. in Immunology and Genetics from Case Western Reserve University, Institute of Pathology and a B.A. in Biology from Swarthmore College.